CA 125치가 증가된 난소종괴 환자에서 악성 감별을 위한 CA 15-3과 TAG 72의 효용성

Abstract

The purpose of our study was to evaluate whether the combined use of serum tumor markers, CA 15-3 and TAG 72 could improve the efficacy for discriminating malignant from benign ovarian masses in patients with elevated serum CA 125 levels.

Serum CA 15-3 and TAG 72 were preoperatively measured by immunoradiometric assay in 78 patients with pelvic masses who had elevated serum CA 125 levels above 35 U/ml.

In 32 patients with epithelial ovarian cancers, serum CA 125 levels were elevated above 65 U/ml in 97% and serum CA 15-3(>30U/ml) and TAG 72(>10 u/ml) levels were elevated in 59% and 50%, respectively, suggesting relatively low sensitivity of CA 15-3 and TAG 72. However, in 41 patients with benign ovarian tumors, elevations of these two markers were detected only in 7% and 5%, respectively, and particularly, both markers were not elevated among all the aptients over 50 years of age. Coordinate elevations of CA 125(>35U/ml) and CA 15-3(>30U/ml) or TAG 72(>10 U/ml) could discriminate epithelial ovarian cancers from benign masses with a sensitivity of 72% and specificity of 90%. Among patients over 50 years of age, sensitivity and specificity were increased to 79% and 100%, respectively.

It is concluded that the combined use of CA 15-3 and TAG 72 with CA 125 could obtain an improved efficacy for discrimination of epithelial ovarian cancer, especially among patients over 50 years of age.

The purpose of our study was to evaluate whether the combined use of serum tumor markers, CA 15-3 and TAG 72 could improve the efficacy for discriminating malignant from benign ovarian masses in patients with elevated serum CA 125 levels.

Serum CA 15-3 and TAG 72 were preoperatively measured by immunoradiometric assay in 78 patients with pelvic masses who had elevated serum CA 125 levels above 35 U/ml.

In 32 patients with epithelial ovarian cancers, serum CA 125 levels were elevated above 65 U/ml in 97% and serum CA 15-3(>30U/ml) and TAG 72(>10 u/ml) levels were elevated in 59% and 50%, respectively, suggesting relatively low sensitivity of CA 15-3 and TAG 72. However, in 41 patients with benign ovarian tumors, elevations of these two markers were detected only in 7% and 5%, respectively, and particularly, both markers were not elevated among all the aptients over 50 years of age. Coordinate elevations of CA 125(>35U/ml) and CA 15-3(>30U/ml) or TAG 72(>10 U/ml) could discriminate epithelial ovarian cancers from benign masses with a sensitivity of 72% and specificity of 90%. Among patients over 50 years of age, sensitivity and specificity were increased to 79% and 100%, respectively.

It is concluded that the combined use of CA 15-3 and TAG 72 with CA 125 could obtain an improved efficacy for discrimination of epithelial ovarian cancer, especially among patients over 50 years of age.